Non Small Cell Lung Cancer News and Research

RSS

Non-Small Cell Lung Cancers are a group of lung cancers that are named for the kinds of cells found in the cancer and how the cells look under a microscope. The three main types of non-small cell lung cancer are squamous cell carcinoma, large cell carcinoma, and adenocarcinoma. Non-small cell lung cancer is the most common kind of lung cancer.

Study may provide a new therapeutic target for treatment of LUAD patients

Aging-US published "A novel ferroptosis-related gene signature for prognostic prediction of patients with lung adenocarcinoma" which reported that RNA-seq transcriptome data of LUAD patients were obtained from The Cancer Genome Atlas database.

9 Aug 2021

Experimental drug combination extends survival in mice with lung cancer, study finds

A combination of experimental drugs increased the attack of immune cells on non-small cell lung cancer (NSCLC) to extend survival in mice, a new study found.

5 Aug 2021

MET amplification identified as a potentially actionable driver for non-small cell lung cancer

A study led by D. Ross Camidge, MD, PhD, director of thoracic oncology at the University of Colorado School of Medicine and CU Cancer Center member, has helped to define MET amplification as a rare but potentially actionable driver for non-small cell lung cancer (NSCLC).

20 Jul 2021

Moffitt awarded $10.2 million grant to investigate lung cancer metabolism

The National Cancer Institute has awarded the Lung Cancer Metabolism Working Group at Moffitt Cancer Center with a Research Program Project Grant (P01CA250984).

28 Jun 2021

Study highlights the impact of structural racism and residential segregation on lung cancer outcomes

Lung cancer remains the leading cause of cancer-related deaths. Non-small cell lung cancer (NSCLC) accounts for 80-85 percent cases of lung cancer and when diagnosed early, has a five-year survival rate of 50-80 percent.

22 Jun 2021

PET/CT images can be used to measure biomarker levels, predict lung cancer outcomes

Tests that analyze biomarkers are used during cancer management to guide treatment and provide information about patient prognosis.

17 Jun 2021

Study uncovers novel drug that effectively thwarts pancreatic tumors

Pancreatic cancer is an aggressive disease in which malignant cells form in the tissues of the pancreas, a long and flat gland located behind the stomach that helps with digestion and blood sugar regulation.

14 Jun 2021

Study: Lung squamous patients harboring druggable mutations have lower median overall survival

Oncotarget published "Molecular characterization of lung squamous cell carcinoma tumors reveals therapeutically relevant alterations" which reported that unlike lung adenocarcinoma patients, there is no FDA-approved targeted-therapy likely to benefit lung squamous cell carcinoma patients.

3 Jun 2021

SWOG researchers to present practice-changing research at virtual ASCO 2021

"SWOG always brings an impressive portfolio of work to the ASCO annual meeting," said SWOG Chair Charles D. Blanke, MD, "and this year I'm particularly excited about the research our investigators are presenting because it includes results that are likely to be practice-changing."

1 Jun 2021

FDA approves targeted therapy for tumors with KRAS mutations

Today, the U.S. Food and Drug Administration approved Lumakras (sotorasib) as the first treatment for adult patients with non-small cell lung cancer whose tumors have a specific type of genetic mutation called KRAS G12C and who have received at least one prior systemic therapy.

29 May 2021

FDA approves Rybrevant for treating subset of non-small cell lung cancer

Today, the U.S. Food and Drug Administration approved Rybrevant (amivantamab-vmjw) as the first treatment for adult patients with non-small cell lung cancer whose tumors have specific types of genetic mutations: epidermal growth factor receptor (EGFR) exon 20 insertion mutations.

21 May 2021

New approach combines molecular and medical imaging data to diagnose cancer type

Despite our remarkable advances in medicine and healthcare, the cure to cancer continues to elude us. On the bright side, we have made considerable progress in detecting several cancers in earlier stages, allowing doctors to provide treatments that increase long-term survival.

11 May 2021

Study identifies novel combination therapy to help patients with advanced lung cancer

A new study by researchers at the UCLA Jonsson Comprehensive Cancer Center has identified a novel combination therapy to potentially help overcome resistance to immunotherapy in people diagnosed with advanced lung cancer.

5 May 2021

New genetic markers may lead to personalized treatments for lung cancer

Investigators at Wake Forest School of Medicine, part of Wake Forest Baptist Health, have identified a set of new genetic markers that could potentially lead to new personalized treatments for lung cancer.

15 Apr 2021

Aneuploidy testing can be key in determining optimal treatment for lung cancer patients

Patients with non-small cell lung cancer (NSCLC) whose cancer cells have low levels of aneuploidy - an abnormal number of chromosomes - tend to respond better to immune checkpoint inhibitor drugs than patients with higher levels, Dana-Farber Cancer Institute researchers will report at the virtual AACR Annual Meeting 2021.

12 Apr 2021

High expression of cell death genes may increase risk of early death from lung cancer

Patients with a high number of genes most associated with pathways that lead to cell death in lung cancer are at increased risk of dying early from their disease, researchers report.

5 Apr 2021

Evidence-based clinical practice guideline aims to optimize PD-L1 lung tumor testing

The College of American Pathologists (CAP), in collaboration with five other societies, developed a draft evidence-based clinical practice guideline that aims to optimize PD-L1 testing for patients with non-small cell lung cancer (NSCLC) who are being considered for immunooncology therapy.

1 Apr 2021

NCCN Annual Conference discusses new ways to improve cancer care

New recommendations to advance racial equity, ways to mitigate the impacts of the COVID-19 pandemic on cancer care, and ongoing strategies for preventing and controlling HPV-associated cancers led the conversation at the National Comprehensive Cancer Network® (NCCN®) 2021 Virtual Annual Conference March 18-20.

25 Mar 2021

Novel method can improve the detection of circulating tumor cells

Non-Small Cell Lung Cancer (NSCLC) is the most prevalent form of lung cancer, accounting for more than 80 percent of all lung cancer cases.

10 Mar 2021

Newly identified biomarker could predict response to immune checkpoint inhibitors

A team of Roswell Park Comprehensive Cancer Center researchers has identified a new biomarker that could predict response to immune checkpoint inhibitors (ICI) shortly after patients with non-small cell lung cancer (NSCLC) initiate therapy.

3 Mar 2021